Pantoprazole
Duodenum Cancer
Washington University School of MedicineSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Duodenum Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
N-Butyl Cyanoacrylate Minia University | Phase 3 | B |
Apixaban Asan Medical Center | Phase 2 | CCC |
Kras Tcr-Transduced Pbl National Cancer Institute (NCI) | Phase 2 | CCC |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | CCC |
Rivaroxaban Asan Medical Center | Phase 2 | CCC |
Dalteparin Asan Medical Center | Phase 2 | CCC |
Fludarabine National Cancer Institute (NCI) | Phase 2 | CCC |
Irinotecan University of Southern California | Phase 1 | CC |
Same molecule, other indications
Pantoprazole is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative · Phase 4
62 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →